<DOC>
	<DOCNO>NCT00460941</DOCNO>
	<brief_summary>This 4 arm study evaluate tolerability , efficacy pharmacodynamics different dos GLP-1 analogue patient type 2 diabetes treat stable dose metformin . Patients randomize receive either subcutaneous placebo , subcutaneous GLP-1 analogue ( dose 20mg , start dose 20mg escalate either 30mg 40mg ) , weekly . All patient continue exist metformin treatment regimen throughout study . The anticipated time study treatment &lt; 3 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Titration Study Glucagon-Like Peptide-1 ( GLP-1 ) Analogue Patients With Type 2 Diabetes Treated With Metformin .</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>male , postmenopausal surgically sterilize female , patient , 1875 year age ; type 2 diabetes mellitus , stable metformin treatment &gt; =3 month ; HbA1c &gt; =7.0 % &lt; =9.5 % screening ; stable weight +/10 % &gt; =3 month screen . type 1 diabetes mellitus ; clinically significant gastrointestinal disease ; treatment antihyperglycemic medication metformin monotherapy last 3 month ; use weightlowering medication last 3 month ; uncontrolled hypertension ; previous exposure GLP1 GLP1 analogue .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>